A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
Latest Information Update: 27 Feb 2024
At a glance
- Drugs MORF 057 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EMERALD-1
- Sponsors Morphic Therapeutic
- 22 Feb 2024 According to a Morphic Therapeutic media release, company announced completion of enrollment in the exploratory cohort of the EMERALD-1 study comprised of UC patients who have previously failed treatment with vedolizumab.
- 22 Feb 2024 According to a Morphic Therapeutic media release, continued the 40-week maintenance phase of the EMERALD-1 study as projected with top-line data anticipated in the first half of 2024, patients who completed the 12-week induction phase of the EMERALD-1 Phase 2a study were eligible to continue participating in a 40-week maintenance phase of the EMERALD-1 open-label single-arm study
- 01 Nov 2023 According to Schrodinger, Inc. media release, data from this study presented in Oct 2023 at United European Gastroenterology (UEG) week.